Vasospasm and stroke attributable to ephedra-free xenadrine: Case report

Military Medicine

Volumn 173, Issue 7, 2008, Pages 708-710

  Holmes Jr , Roben O ^a   Tavee, Jinny ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; NUTRACEUTICAL; OXEDRINE; XENADRINE;

ADULT; ARTICLE; BRAIN VASOSPASM; CASE REPORT; CLINICAL FEATURE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPHEDRA; FEMALE; HUMAN; MIDDLE CEREBRAL ARTERY; STROKE;

EID: 47749127294     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.173.7.708     Document Type: Article

References (19)

1. American Obesity Association: U.S. obesity trends. Available at http://www.obesity.org/statistics/obesity_trends.asp; accessed February 28, 2007.
2. Walsh N: Ephedra substitute may put dieters at similar risk: has stimulant effects, drug interactions. Intern Med News 2004; 37: 1-2.
3. Schievink WI, Maya MM, Chow W, Louy C: Reversible cerebral vasoconstriction in spontaneous intracranial hypotension. Headache 2007; 47: 284-7.
4. Ito T, Sakai T, Inagawa S, Utsu M, Bun T: MR angiography of cerebral vasospasm in preeclampsia. AJNR Am J Neuroradiol 1995; 16: 1344-6.
5. Henderson RD, Rajah T, Nicol AJ, Read SJ: Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology 2003; 60: 326-8.
6. Waltz AG: Effect of blood pressure on blood flow in ischemic and in nonischemic cerebral cortex: the phenomena of autoregulation and luxury perfusion. Neurology 1968; 18: 613-21.
7. Ells LJ, Lang R, Shield JPH, et al: Obesity and disability: a short review. Obes Rev 2006; 7: 341-5.
8. Associated Press: Diet pill makers fined millions for false claims: marketers of popular weight loss drugs misled consumers, FTC says, January 4, 2007. Available at http://www.msnbc.msn.com/id/16467558; accessed February 28, 2007.
9. Haller CA, Benowitz NL, Jacob P III: Hemodynamic effects of ephedra-free weight loss supplements in humans. Am J Med 2005; 118: 998-1003.
10. Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS: Herbal medicines: stroke associated with a synephrine-containing weight loss preparation: case report. Reactions 2005; 1(1054): 10.
11. Food and Drug Administration: MedWatch. Available at http://www.fda.gov/ oc/initiatives/ephedra/february2004/qa_020604.html; accessed February 2007.
12. Huang YT, Wang GF, Chen CF, Chen CC, Hong CY, Yang MC: Fructus aurantii reduced pressure in portal hypertensive rats. Life Sci 1995; 57: 2011-20.
13. Fang F, Dong M, Zhu H: Effect of Citrus aurantium extract on L-type calcium currents in ventricular myocytes of single guinea pigs [in Chinese]. Hunan Yi Ke Da Xue Xue Bao 2003; 28: 353-6.
14. Bent S, Padula A, Neuhaus J: Safety and efficacy of Citrus aurantium for weight loss. Am J Cardiol 2004; 94: 1359-61.
15. Hamilton RJ: Exercise-induced syncope associated with QT prolongation and ephedra-free xenadrine. Ann Emerg Med 2005; 46: 99-100.
16. Nasir JM, Durning SJ, Ferguson M, Barold HS, Haigney MC: Exercise-induced syncope associated with QT prolongation and ephedra-free xenadrine. Mayo Clinic Proc 2004; 79: 1059-62.
17. Fugh-Berman A, Myers A: Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med (Maywood) 2004; 229: 698-704.
18. Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS: Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proc 2005; 80: 541-5.
19. Preuss HG, DiFerdinando D, Bagchi M, Bagchi D: Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview. J Med 2002; 33: 247-64.